Anne Derache
French Institute of Health and Medical Research
18 Papers
147 Citations
Anne Derache is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Medicine & Lamivudine. The author has an hindex of 12, co-authored 17 publications. Previous affiliations of Anne Derache include University of Paris & University of KwaZulu-Natal.
Chat about Author
Papers
Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali
David Germanaud,Anne Derache,Mamadou Traore,Yoann Madec,Safiatou Toure,Fatoumata Dicko,Hadizatou Coulibaly,Malick Traore,Mariam Sylla,Vincent Calvez,Anne-Geneviève Marcelin +10 more
TL;DR: Under NNRTI-based regimens, early detection of VF could allow the reinforcement of adherence when VL was <1000 copies/mL, because in most of these cases no resistance mutations were detected, and the low frequency of TAMs suggests that most NRTIs can be used in a second-line regimen after early failure.
62
Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis
Silvia Bertagnolio,Lucas E Hermans,Lucas E Hermans,Michael R. Jordan,Michael R. Jordan,Santiago Ávila-Ríos,Collins Iwuji,Anne Derache,Eric Delaporte,Annemarie M. J. Wensing,Annemarie M. J. Wensing,Theresa Aves,A S M Borhan,Alvin Leenus,Neil Parkin,Meg Doherty,Seth C Inzaule,Lawrence Mbuagbaw +17 more
TL;DR: It is found that individuals with PDR initiating NNRTIs across all the subgroups had increased risk of virological failure compared to those without PDR, supporting the World Health Organization’s recommendation to avoid using NN RTIs in countries where levels of PDR are high.
56
Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes
Almoustapha Issiaka Maiga,Almoustapha Issiaka Maiga,Diane Descamps,Laurence Morand-Joubert,Isabelle Malet,Anne Derache,Mamadou Cisse,Victoria Koita,Alain Akonde,Bah Diarra,Marc Wirden,Anatole Tounkara,Yvan Verlinden,Christine Katlama,Dominique Costagliola,Bernard Masquelier,Vincent Calvez,Anne-Geneviève Marcelin +17 more
TL;DR: Although the prevalence of ETR RAMs in treatment-naïve patients infected with non-B HIV-1 subtypes was 10%, in most cases this had no significant impact on ETR susceptibility, however, the transmission of drug-resistant viruses with Y181C in a non- B genetic background has a potential for impact onETR susceptibility.
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
Anne-Geneviève Marcelin,Bernard Jarrousse,Anne Derache,Madina Ba,Marie-léa Dakouo,Alioune Doumbia,Ibrahima Haidara,Almoustapha Issiaka Maiga,Guislaine Carcelain,Gilles Peytavin,Christine Katlama,Vincent Calvez +11 more
TL;DR: The importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options is highlighted.
39
T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy.
Gila Lustig,Sandile Cele,Farina Karim,Anne Derache,Abigail Ngoepe,Khadija Khan,Bernadett I Gosnell,Mahomed-Yunus S. Moosa,Ntombi Ntshuba,Suzaan Marais,Prakash Jeena,Katya Govender,John H. Adamson,Henrik N. Kløverpris,Henrik N. Kløverpris,Ravindra K. Gupta,Rohen Harrichandparsad,Vinod B. Patel,Alex Sigal,Alex Sigal +19 more
TL;DR: In this article, the authors detected host cell surface markers on the HIV envelope to determine the cellular source of HIV in participants on the first line regimen of efavirenz, emtricitabine, and tenofovir.